| pubmed-article:6362841 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C1518578 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C0010927 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C0009429 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C0677874 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C0442711 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C0205099 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C0205087 | lld:lifeskim |
| pubmed-article:6362841 | lifeskim:mentions | umls-concept:C0556895 | lld:lifeskim |
| pubmed-article:6362841 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:6362841 | pubmed:dateCreated | 1984-3-23 | lld:pubmed |
| pubmed-article:6362841 | pubmed:abstractText | The results of three Phase III studies of DTIC in 580 patients with metastatic melanoma were reviewed to evaluate the subsequent course of 26 patients who achieved a complete response (CR) to chemotherapy. The majority (17 of 26) of these patients had soft tissue metastases. Six of the 26 patients remained in CR at last report (30-259 weeks), two died of other causes while remaining free of melanoma, and 18 relapsed and died. Ninety-five percent of the 26 patients were alive at 1 year, and survival was 31.1% at 72 months. Seven of the eight patients with sustained remission received chemotherapy for at least 6 months after CR developed, whereas 10 of 18 relapsing patients were treated for less than 6 months after CR was achieved. Long-term sustained CR to chemotherapy occurs in 1% to 2% of patients treated with DTIC, and late relapse is rare in patients who remain in CR for 2 years. | lld:pubmed |
| pubmed-article:6362841 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6362841 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6362841 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6362841 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:6362841 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6362841 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6362841 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6362841 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6362841 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6362841 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6362841 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:6362841 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:6362841 | pubmed:author | pubmed-author:HillH ZHZ | lld:pubmed |
| pubmed-article:6362841 | pubmed:author | pubmed-author:KrementzE TET | lld:pubmed |
| pubmed-article:6362841 | pubmed:author | pubmed-author:HillG JGJ2nd | lld:pubmed |
| pubmed-article:6362841 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6362841 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:6362841 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:6362841 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6362841 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6362841 | pubmed:pagination | 1299-305 | lld:pubmed |
| pubmed-article:6362841 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:meshHeading | pubmed-meshheading:6362841-... | lld:pubmed |
| pubmed-article:6362841 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6362841 | pubmed:articleTitle | Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). | lld:pubmed |
| pubmed-article:6362841 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6362841 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:6362841 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:6362841 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6362841 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6362841 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6362841 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6362841 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6362841 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6362841 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6362841 | lld:pubmed |
